Simcerely Yours: Simcere Buys Majority Stake In Fellow Chinese Pharma Boda
This article was originally published in The Pink Sheet Daily
CEO Ren continues acquisition strategy, giving Simcere control of the entire Chinese injectable edaravone market.
You may also be interested in...
Consolidation could shrink China’s pharmaceutical industry from 4,000 firms today to as few as 1,000 in future, Simcere CEO tells investors at Goldman Sachs conference.
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.